Multiple myeloma

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Cristina Gasparetto, Carol Ann Huff, Madan Jagasia, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Guido Tricot, Julie Marie VoseDonna Weber, Joachim Yahalom, Furhan Yunus

Research output: Contribution to journalReview article

60 Citations (Scopus)

Abstract

Although MM is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treating patients enrolled in clinical research protocols.

Original languageEnglish (US)
Pages (from-to)908-942
Number of pages35
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue number9
DOIs
StatePublished - Oct 2009

Fingerprint

Multiple Myeloma
Therapeutics
Clinical Protocols
Radiotherapy
Quality of Life
Guidelines
Drug Therapy

Keywords

  • Bisphosphonates
  • C-reactive protein
  • Combination chemotherapy
  • Cytogenetics
  • Immunomodulatory drugs
  • Multiple myeloma
  • NCCN Clinical Practice Guidelines
  • Novel therapies
  • Primary amyloidosis
  • Proteasome inhibitor
  • Stem cell transplant
  • Supportive therapies
  • Waldenström's monoclonal protein

ASJC Scopus subject areas

  • Oncology

Cite this

Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., ... Yunus, F. (2009). Multiple myeloma. JNCCN Journal of the National Comprehensive Cancer Network, 7(9), 908-942. https://doi.org/10.6004/jnccn.2009.0061

Multiple myeloma. / Anderson, Kenneth C.; Alsina, Melissa; Bensinger, William; Biermann, J. Sybil; Chanan-Khan, Asher; Cohen, Adam D.; Devine, Steven; Djulbegovic, Benjamin; Gasparetto, Cristina; Huff, Carol Ann; Jagasia, Madan; Medeiros, Bruno C.; Meredith, Ruby; Raje, Noopur; Schriber, Jeffrey; Singhal, Seema; Somlo, George; Stockerl-Goldstein, Keith; Tricot, Guido; Vose, Julie Marie; Weber, Donna; Yahalom, Joachim; Yunus, Furhan.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 7, No. 9, 10.2009, p. 908-942.

Research output: Contribution to journalReview article

Anderson, KC, Alsina, M, Bensinger, W, Biermann, JS, Chanan-Khan, A, Cohen, AD, Devine, S, Djulbegovic, B, Gasparetto, C, Huff, CA, Jagasia, M, Medeiros, BC, Meredith, R, Raje, N, Schriber, J, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Tricot, G, Vose, JM, Weber, D, Yahalom, J & Yunus, F 2009, 'Multiple myeloma', JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 9, pp. 908-942. https://doi.org/10.6004/jnccn.2009.0061
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD et al. Multiple myeloma. JNCCN Journal of the National Comprehensive Cancer Network. 2009 Oct;7(9):908-942. https://doi.org/10.6004/jnccn.2009.0061
Anderson, Kenneth C. ; Alsina, Melissa ; Bensinger, William ; Biermann, J. Sybil ; Chanan-Khan, Asher ; Cohen, Adam D. ; Devine, Steven ; Djulbegovic, Benjamin ; Gasparetto, Cristina ; Huff, Carol Ann ; Jagasia, Madan ; Medeiros, Bruno C. ; Meredith, Ruby ; Raje, Noopur ; Schriber, Jeffrey ; Singhal, Seema ; Somlo, George ; Stockerl-Goldstein, Keith ; Tricot, Guido ; Vose, Julie Marie ; Weber, Donna ; Yahalom, Joachim ; Yunus, Furhan. / Multiple myeloma. In: JNCCN Journal of the National Comprehensive Cancer Network. 2009 ; Vol. 7, No. 9. pp. 908-942.
@article{8e0246ac2d8c4f58867343ec1b9b00fd,
title = "Multiple myeloma",
abstract = "Although MM is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treating patients enrolled in clinical research protocols.",
keywords = "Bisphosphonates, C-reactive protein, Combination chemotherapy, Cytogenetics, Immunomodulatory drugs, Multiple myeloma, NCCN Clinical Practice Guidelines, Novel therapies, Primary amyloidosis, Proteasome inhibitor, Stem cell transplant, Supportive therapies, Waldenstr{\"o}m's monoclonal protein",
author = "Anderson, {Kenneth C.} and Melissa Alsina and William Bensinger and Biermann, {J. Sybil} and Asher Chanan-Khan and Cohen, {Adam D.} and Steven Devine and Benjamin Djulbegovic and Cristina Gasparetto and Huff, {Carol Ann} and Madan Jagasia and Medeiros, {Bruno C.} and Ruby Meredith and Noopur Raje and Jeffrey Schriber and Seema Singhal and George Somlo and Keith Stockerl-Goldstein and Guido Tricot and Vose, {Julie Marie} and Donna Weber and Joachim Yahalom and Furhan Yunus",
year = "2009",
month = "10",
doi = "10.6004/jnccn.2009.0061",
language = "English (US)",
volume = "7",
pages = "908--942",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - Multiple myeloma

AU - Anderson, Kenneth C.

AU - Alsina, Melissa

AU - Bensinger, William

AU - Biermann, J. Sybil

AU - Chanan-Khan, Asher

AU - Cohen, Adam D.

AU - Devine, Steven

AU - Djulbegovic, Benjamin

AU - Gasparetto, Cristina

AU - Huff, Carol Ann

AU - Jagasia, Madan

AU - Medeiros, Bruno C.

AU - Meredith, Ruby

AU - Raje, Noopur

AU - Schriber, Jeffrey

AU - Singhal, Seema

AU - Somlo, George

AU - Stockerl-Goldstein, Keith

AU - Tricot, Guido

AU - Vose, Julie Marie

AU - Weber, Donna

AU - Yahalom, Joachim

AU - Yunus, Furhan

PY - 2009/10

Y1 - 2009/10

N2 - Although MM is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treating patients enrolled in clinical research protocols.

AB - Although MM is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treating patients enrolled in clinical research protocols.

KW - Bisphosphonates

KW - C-reactive protein

KW - Combination chemotherapy

KW - Cytogenetics

KW - Immunomodulatory drugs

KW - Multiple myeloma

KW - NCCN Clinical Practice Guidelines

KW - Novel therapies

KW - Primary amyloidosis

KW - Proteasome inhibitor

KW - Stem cell transplant

KW - Supportive therapies

KW - Waldenström's monoclonal protein

UR - http://www.scopus.com/inward/record.url?scp=72149104327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149104327&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2009.0061

DO - 10.6004/jnccn.2009.0061

M3 - Review article

C2 - 19878637

AN - SCOPUS:72149104327

VL - 7

SP - 908

EP - 942

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 9

ER -